Prostate Cancer Reports


Volume 2 Supplement 10
  October 2014

Home > Prostate Cancer Reports > Volume 2 - Year 2014 > Supplement 10, October 2014

CONTENTS


Etiology and pathogenesis
Prognosis and outcome
Treatment


ETIOLOGY AND PATHOGENESIS



Barbieri CE, Demichelis F, Rubin MA.
The Lethal Clone in Prostate Cancer: Redefining the Index.
Eur Urol. 2014 Jan 2. pii: S0302-2838(13)01462-0. doi: 10.1016/j.eururo.2013.12.052. [Epub ahead of print]
Abstract | Full text | Related citations


Brannon AR, Sawyers CL.
"N of 1" case reports in the era of whole-genome sequencing.
J Clin Invest. 2013 Nov 1;123(11):4568-70. doi: 10.1172/JCI70935. Epub 2013 Oct 25.
Abstract | Full text | Related citations


Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gürel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S.
Tracking the clonal origin of lethal prostate cancer.
J Clin Invest. 2013 Nov 1;123(11):4918-22. doi: 10.1172/JCI70354. Epub 2013 Oct 25.
Abstract | Full text | Related citations


Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR.
A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling.
Eur Urol. 2014 May 16. pii: S0302-2838(14)00414-X. doi: 10.1016/j.eururo.2014.05.004. [Epub ahead of print]
Abstract | Full text | Related citations


Klein EA, Cooperberg MR, Carroll PR.
Reply to Yuri Tolkach, Markus Kuczyk, Florian Imkamp's Letter to the Editor re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. Eur Urol 2014;66:550-60.
Eur Urol. 2014 Aug 19. pii: S0302-2838(14)00743-X. doi: 10.1016/j.eururo.2014.08.001. [Epub ahead of print]
Abstract | Related citations


Lindberg J, Kristiansen A, Wiklund P, Grönberg H, Egevad.
Tracking the Origin of Metastatic Prostate Cancer.
European Urology, 2014 Sep 20. Epub
Abstract


Tolkach Y, Kuczyk M, Imkamp F.
Re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. Eur Urol 2014;66:550-60.
Eur Urol. 2014 Aug 16. pii: S0302-2838(14)00744-1. doi: 10.1016/j.eururo.2014.08.002. [Epub ahead of print]
Abstract | Related citations


Taneja SS.
Re: tracking the clonal origin of lethal prostate cancer.
J Urol. 2014 May;191(5):1286-9. doi: 10.1016/j.juro.2014.02.078. Epub 2014 Feb 22.
Abstract | Related citations

PROGNOSIS AND OUTCOME



Giannarini G, Suardi N, Briganti A.
Re: Prasanna Sooriakumaran, Abhishek Srivastava, Shahrokh F. Shariat, et al. A multinational, multi-institutional study comparing positive surgical margin rates among 22,393 open, laparoscopic, and robot-assisted radical prostatectomy patients. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.11.018.
Eur Urol. 2014 Jun;65(6):e89-90. doi: 10.1016/j.eururo.2014.01.004. Epub 2014 Jan 15. No abstract available.
Abstract | Full text | Related citations


Graefen M, Huland H.
A positive surgical margin following radical prostatectomy should not routinely be the indication for adjuvant radiation therapy.
Eur Urol. 2014 Apr;65(4):681-2. doi: 10.1016/j.eururo.2013.09.020. Epub 2013 Sep 20.
Abstract | Full text | Related citations


Hansen J, Bianchi M, Sun M, Rink M, Castiglione F, Abdollah F, Steuber T, Ahyai SA, Steurer S, Göbel C, Freschi M, Montorsi F, Shariat SF, Fisch M, Graefen M, Karakiewicz PI, Briganti A, Chun FK.
Percentage of high-grade tumour volume does not meaningfully improve prediction of early biochemical recurrence after radical prostatectomy compared with Gleason score.
BJU Int. 2014 Mar;113(3):399-407. doi: 10.1111/bju.12424. Epub 2013 Dec 2.
Abstract | Related citations


Hu XH, Cammann H, Meyer HA, Jung K, Lu HB, Leva N, Magheli A, Stephan C, Busch J.
Risk prediction models for biochemical recurrence after radical prostatectomy using prostate-specific antigen and Gleason score.
Asian J Androl. 2014 Jul 4. doi: 10.4103/1008-682X.129940. [Epub ahead of print]
Abstract | Full text | Related citations


Müller G, Rieken M, Bonkat G, Gsponer JR, Vlajnic T, Wetterauer C, Gasser TC, Wyler SF, Bachmann A, Bubendorf L.
Maximum tumor diameter adjusted to the risk profile predicts biochemical recurrence after radical prostatectomy.
Virchows Arch. 2014 Aug 17. [Epub ahead of print]
Abstract | Related citations


Servoll E, Vlatkovic L, Sæter T, Nesland JM, Axcrona U, Waaler G, Axcrona K.
The Length of a Positive Surgical Margin Is of Prognostic Significance in Patients with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy.
Urol Int. 2014 Aug 27. [Epub ahead of print]
Abstract | Related citations


Sooriakumaran P, Wiklund P, Roobol MJ, Steyerberg E, Sanchez-Salas R, Cathelineau X, Tewari AK.
Reply to Gianluca Giannarini, Nazareno Suardi and Alberto Briganti's letter to the editor re: Prasanna Sooriakumaran, Abhishek Srivastava, Shahrokh F. Shariat, et al. A multinational, multi-institutional study comparing positive surgical margin rates among 22 393 open, laparoscopic, and robot-assisted radical prostatectomy patients. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.11.018.
Eur Urol. 2014 Jun;65(6):e91-2. doi: 10.1016/j.eururo.2014.01.005. Epub 2014 Jan 15. No abstract available.
Abstract | Full text | Related citations


Stephenson AJ, Eggener SE, Hernandez AV, Klein EA, Kattan MW, Wood DP Jr, Rabah DM, Eastham JA, Scardino PT
Do Margins Matter? The Influence of Positive Surgical Margins on Prostate Cancer-Specific Mortality.
Eur Urol. 2013 Aug 27. doi:pii: S0302-2838(13)00864-6. 10.1016/j.eururo.2013.08.036. [Epub ahead of print]
Abstract | Full text | Related citations


Yamamoto Y, Nakayama M, Ueda N, Takeda K, Nakata W, Kakimoto K, Nishimura K.
[Risk factors of recurrence after radical prostatectomy for locally advanced prostate cancer].
Nihon Hinyokika Gakkai Zasshi. 2014 Jul;105(3):91-6. Japanese.
Abstract | Related citations


Biochemical recurrence after salvage radiotherapy

Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Sun M, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T.
Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy.
Eur Urol. 2014 Sep 1. pii: S0302-2838(13)01309-2. doi: 10.1016/j.eururo.2013.11.045. [Epub 2013 Dec 12]
Abstract | Full text | Related citations


Kwon O, Kim KB, Lee YI, Byun SS, Kim JS, Lee SE, Hong SK.
Salvage radiotherapy after radical prostatectomy: prediction of biochemical outcomes.
PLoS One. 2014 Jul 29;9(7):e103574. doi: 10.1371/journal.pone.0103574. eCollection 2014.
Abstract | Full text | Related citations


Parker CC, Sydes MR.
Postoperative radiotherapy after radical prostatectomy: let's work together to tackle the known unknowns.
Eur Urol. 2014 Jun;65(6):1044-5. doi: 10.1016/j.eururo.2013.09.035. Epub 2013 Sep 27.
Abstract | Full text | Related citations


Williams SB, Hu JC.
Predicting Biochemical Recurrence Following Salvage Radiotherapy: Applying Lessons Learned from Primary Radiotherapy.
Eur Urol. 2014 Jan 2. pii: S0302-2838(13)01458-9. doi: 10.1016/j.eururo.2013.12.048. [Epub ahead of print]
Abstract | Full text | Related citations

TREATMENT



Castration-resistant PCa

Overview

Bastos DA, Dzik C, Rathkopf D, Scher HI.
Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
Oncology (Williston Park). 2014 Aug;28(8):693-9.
Abstract | Full text | Related citations


Cheng HH, Higano CS.
Targeting the androgen receptor signaling axis to reduce testosterone levels in prostate cancer: how low should we go?
Oncology (Williston Park). 2014 Aug;28(8):700-1.
Abstract | Full text | Related citations


Crawford ED.
Small steps that lead to a giant leap for prostate cancer patients.
Oncology (Williston Park). 2014 Aug;28(8):652.
Abstract | Full text | Related citations


Moul JW.
The urology perspective on expanding androgen-targeted treatments for men with castration-resistant prostate cancer.
Oncology (Williston Park). 2014 Aug;28(8):702-3, 722.
Abstract | Full text | Related citations


Cabazitaxel

Jones RJ.
Sequencing Systemic Therapies in Advanced Prostate Cancer: Spoiled for Choice But Not for Evidence.
Eur Urol. 2014 Jan 2. pii: S0302-2838(13)01463-2. doi: 10.1016/j.eururo.2013.12.053. [Epub ahead of print]
Abstract | Full text | Related citations


Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, de Bono JS, Attard G.
Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents.
Eur Urol. 2013 Dec 17. pii: S0302-2838(13)01308-0. doi: 10.1016/j.eururo.2013.11.044. [Epub ahead of print]
Abstract | Full text | Related citations


Metformin

Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bärtschi D, Pollak M, Lui L, Endt K, Schiess R, Rüschoff JH, Cathomas R, Gillessen S.
Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09).
Eur Urol. 2014 Jan 4. pii: S0302-2838(13)01482-6. doi: 10.1016/j.eururo.2013.12.057. [Epub ahead of print]
Abstract | Full text | Related citations


Hamilton RJ.
Metformin for Castrate-resistant Prostate Cancer: Learning More About an Old Dog's New Tricks.
Eur Urol. 2014 Jan 23. pii: S0302-2838(14)00025-6. doi: 10.1016/j.eururo.2014.01.013. [Epub ahead of print]
Abstract | Full text | Related citations


Rothermundt C; on behalf of all the authors.
Reply from Authors re: Robert J. Hamilton. Metformin for Castrate-resistant Prostate Cancer: Learning More About an Old Dog's New Tricks. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.013: The Stage Is Set for Metformin.
Eur Urol. 2014 Jan 28. pii: S0302-2838(14)00093-1. doi: 10.1016/j.eururo.2014.01.024. [Epub ahead of print]
Abstract | Full text | Related citations